Young Entrepreneur with CMT1A Launches Company

by | Jan 9, 2021 | 0 comments

Dakota Reilly is a young adult based in New York who has CMT1A.

After graduating from the Fashion Institute of Technology and working in the fashion industry, Dakota realized how much she enjoys creating her own products. Since working from home is ideal for someone who has difficulty commuting, especially in New York City, Dakota decided to create her own business, Blue Bear.

Dakota launched Blue Bear in August 2020 with a full line of greeting cards, stickers and enamel pins. The products are fun and unique, with the goal of brightening your day. If you are inspired by iced coffee, plants, or a cute laptop case, you will definitely love Blue Bear. There are greeting cards for several occasions, and the stickers are weather-proof so they are great for anything you want to customize, such as a laptop, phone, or water bottle.

To check out Blue Bear’s products, please visit bluebeargifts.com. Blue Bear can also be found on Facebook and Instagram at @bluebeargifts.

Learn more on this topic

Related Blog Posts

The Long Road to Diagnosis Renews Dedication to Advocacy

The Long Road to Diagnosis Renews Dedication to Advocacy

Growing up we called it “Steffi disorder.” My friends and family were as baffled as my expert neurologists. I had been diagnosed with typical Spiral Muscular Atrophy (SMA) as a toddler but never followed its progression; I never seemed to get weaker. My myriad of symptoms was distinctly different than anyone else’s I had ever met in a lifetime living in the neuromuscular community. I thought I might never find my true diagnosis, let alone others who share it with me.

Q & A with Andy Heck

Q & A with Andy Heck

Our Q&A for the Winter CMT Update is Andy Heck. Andy has been diagnosed with Charcot-Marie-Tooth since four and doesn’t let CMT stop him for living his life to the fullest!

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news